This recording is from one of our Spotlights Open Series Webinars. If you aren’t signed up to be notified about future Open Webinars, please register here. To view all recordings from this series, click here.

Little is known about the durability of GLP-1’s impact on improved mortality risk. There appears to be a behavioral risk gap between adherence and consistent GLP-1 usage. A credible actuarial framework for post-GLP-1 trajectories is needed, especially for segmentation of “completers vs. drop-offs.” Is there a gap in outcomes between clinical efficacy and real-world use cases? Is risk worse than baseline after discontinuation? Is there an adverse mortality effect post usage? How can wellness programs fill in the gaps?